4D Pharma Interview: why the science should win, ShareBuyers, 24 November 2020

CEO Duncan Peyton speaks to ShareBuyers about recent positive IBS results, 4D's upcoming NASDAQ listing in early 2021, and what’s next for 4D

US listing set to support and accelerate ongoing development of 4D Pharma’s live biotherapeutics, BioPharma Reporter, 3 November

CEO Duncan Peyton speaks to BioPharma-Reporter about what the Longevity (NASDAQ: LOAC) merger and NASDAQ listing mean for 4D pharma

Gut feeling: why microbiomes holds so much promise for targeted therapeutics, Drug Discovery World, 3 November 2020

4D pharma spoke to Lu Rahman about the growing significance of microbiomics in the quest for new therapeutics

4D pharma announces merger with Longevity SPAC and intention to list on NASDAQ, 22 October 2020

Covered by:

Endpoints News

The Pharma Letter

Proactive Investors USA

BioProcess International

Drug Discovery World

The Fourth Therapeutic Class: Live Biotherapeutics, The Medicine Maker, 19 October 2020

The Medicine Maker takes a deep dive into 4D pharma and its functionality-driven approach to Live Biotherapeutic development, including manufacturing, regulation, and the huge potential for the field in the near future

Going for growth! 4D pharma: the pioneering live biotherapeutics trailblazer ready to realise its true value, 15 September 2020

4D pharma is featured in Sharebuyers' Going For Growth series, spotlighting companies which have shown strong growth potential in recent months. We discuss the significant opportunities presented by Live Biotherapeutics and 4D's leading position, some of the unique challenges, and a number of exciting growth catalysts on the horizon

Revolutionary new medicines from the human gut microbiome, 1 September 2020

4D pharma's programs in oncology (MRx0518 and neurodegenerative disease (MRx0029 & MRx0005), feature in Nature BioPharma DealMakers. View online via the link above, or download the PDF

4D pharma reveals 'phenomenal results' from early stage cancer trial, 26 August 2020

CEO Duncan Peyton talks with Proactive's Katie Pilbeam about 4D's positive clinical benefit data for lead immuno-oncology candidate MRx0518 in combination with immune checkpoint inhibitor Keytruda

Also covered Proactive Investors' Ian Lyall

4D pharma: A clinical stage innovator and pioneer of Live Biotherapeutics, 8 June 2020

4D's CEO Duncan Peyton discusses the advantages of 4D's unique approach to Live Biotherapeutics with Proactive Investors

4D pharma PLC about to start dosing patients in its Phase II trial for COVID-19, 29 May 2020

Watch Proactive Investor's Andrew Scott interview 4D's CEO, Duncan Peyton, discussing the company's recent progress in the clinic in oncology and IBS, its Phase II clinical trial in COVID-19, and more

4D pharma receives MHRA approval for Phase II COVID-19 trial

European Pharmaceutical Review, 22 April 2020

BioCentury, 21 April 2020

Pharma Business International, 20 April 2020

Pharmafield, 20 April 2020

Contract Pharma, 20 April 2020

BioSpace: 4D pharma Presents Additional Interim Clinical Data From Combination Study for Lead Oncology Candidate, 17 March 2020

4D presents additional data from its ongoing Phase I/II trial of LBP MRx0518 in combination with Keytruda® at Chardan's virtual 2nd Annual Microbiome Medicines Summit